Tranzactioneaza Docusign Inc (US.DOCU) - 78.4 USD (%) Tranzactioneaza

Docusign a incheiat primul trimestru al anului fiscal&nbsp cu cresteri la nivel operational, influentate in principal de veniturile din abonamente cat si de rata de crestere scazuta a costurilor. Compania si-a crescut totodata programul de rascumparare a actiunilor pana la 1 mld. USD.&nbsp

DocuSign a incheiat cel de-al treilea trimestru al anului fiscal 2024 cu un profit net de 29.8 mil. USD comparativ cu pierderea neta inregistrata in aceeasi perioada din anul fiscal anterior, in timp ce veniturile au marcat o usoara crestere de 9% vs T3 AF2023. Compania se asteapta la o imbunatat...

Actiunile DocuSign au crescut cu 3.5% in sedinta de tranzactionare extinsa, dupa ce ultimele rezultate financiare trimestriale au depasit asteptarile analistilor. Pentru intregul an fiscal, compania anticipeaza o crestere a veniturilor cu un ritm mai lent decat in an...

Pentru T1 al anului fiscal (AF) 2024, DocuSign a raportat rezultate peste asteptarile analistilor. Veniturile trimestriale au crescut cu 12%, pana la 661.4 mil. USD, iar EPS ajustat a fost de 0.72 USD/actiune, mai mult fata de valoarea anticipata de 0.56 USD/actiune. Compania a raportat peste 1 mld. utilizatori, in data de 30 aprilie, din care 1.4 mil. utilizatori achita bani pentru serviciile sale. Pentru urmatorul trimestru, compania anticipeaza venituri cuprinse intre 675 – 679 mil. USD, in timp ce, la nivelul intregului an fiscal, se asteapta la venituri cuprinse intre 2.71 – 2.73 mld. USD, peste estimarile de 2.7 mld. USD ale analistilor. In plus, compania va lansa noi produse si servicii. Dupa publicarea rezultatelor, cotatia actiunilor companiei a crescut cu putin peste 5%. (Sursa: docusign docu q1 earnings report 2024 2023)

DocuSign, companie furnizoare de semnaturi electronice, a incheiat anul fiscal 2023 raportand venituri totale record de 2.5 mld. USD (+19% vs. AF 2022), dupa ce veniturile din abonamente au crescut cu 20% fata de perioada anterioara, pana la 2.4 mld. USD. Marja bruta (non-GAAP) s-a stabilizat la 82%, nivel inregistrat si in anul fiscal 2022. EPS (non-GAAP) a fost de 2.03 USD/actiune, in crestere cu 2.5%, atingand un nivel record. Pentru anul fiscal 2024, compania anticipeaza ca va atinge un nou record al veniturilor totale, acestea fiind previzionate in intervalul 2.70 – 2.71 mld. USD. Totodata, DocuSign anticipeaza ca EPS (non-GAAP) se va situa in intervalul 2.07 – 2.14. (Surse: DocuSign Announces Fourth Quarter and Fiscal Year Financial Results2023 default )

Here is his list of the top five best performers in the Nasdaq 100:

1. Vertex Pharmaceuticals (US.VRTX)
2. Activision Blizzard&nbsp
3. T-Mobile (US.TMUS)
4. Constellation Energy&nbsp (US.CEG)
5. Seagen (US.SGENN)

1. Netflix (US.NFLX)
2. Align Technology (US.ALGN)
3. PayPal (US.PYPL)
4. DocuSign (US.DOCU)
5. Okta (US.OKTA)

jim cramer says investors should eye these three tech names in the nasdaq 100 2022

Venture capitalist Kevin O’Leary believes trying to give the market time is futile. “I can’t do it at market time. I can’t. I’ve tried many times, but you can’t,” O’Leary, chairman of O’Leary Ventures, told CNBC’s Squawk Box Asia on Thursday. I like owning companies that I think are sustainable. “The companies I want to own are not going to be empty. Modern (US.MRNA) is not going to be zero, Pfizer (US.PFE) is not going to be zero and Nestle is not going to be zero. They have businesses that are very sustainable, “said O’Leary. Moderna and Pfizer are both pharmaceutical firms – a sector that often has significant cash flows and fixed dividends and, as such, is seen as more resilient during recessions.&nbsp

On Friday, the US Food and Drug Administration approved Pfizer’s three-dose vaccine for children aged 6 months to 4 years and the modern two-dose vaccine for children aged 6 months to 5 years. When the healthcare sector is around 20%, investors like consumer products like Nestle because they are less affected by the economic cycle and enjoy relatively stable earnings growth and dividend payments. “I own companies with strong balance sheets that make money. Now their stock prices are rising based on human perception and what should be the ratio of earnings to price.&nbsp

Even healthcare has not survived the recession But the companies are strong, “he said. In addition to their strong balance sheets, O’Leary also favors these companies for their good cash flow – a portion of which is distributed to investors as dividends. Three stocks are in the red this year, but Nestl. And Pfizer continues to pay dividends. Nestle’s dividend is 2.6%, while Pfizer’s 3.4% ৷ Moderna does not currently pay a dividend. ‘No more than 20% in any one sector.’ But O’Leary is not bothered by short-term price reductions. In fact, he is doubling down on the names he believes in. What I do is I try and find re-entry points because I always try to raise capital. If I believe in the company’s story, I’ll put more money into the correction, “he said. O’Leary said he recently bought undisclosed shares in Walt Disney (US.DIS), Adobe (US.ADBE) and DocuSign (US.DOCU). Unsurprisingly, they will return at some point. He is also wary of how he manages risk in his portfolio. “You need to diversify,” he said. His golden rule? ” No, “he said, describing it as a strategy that has worked for him for decades.”

kevin oleary buy these stocks with strong balance sheets cash flow 2022